[{"orgOrder":0,"company":"AGC Biologics","sponsor":"Trefoil Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"TTHX1114","moa":"FGF1","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"AGC Biologics \/ Trefoil Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"AGC Biologics \/ Trefoil Therapeutics"},{"orgOrder":0,"company":"Exegenesis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"EXG102-031","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Exegenesis Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Injection","sponsorNew":"Exegenesis Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Exegenesis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Avirmax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ABI-201","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Avirmax","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Avirmax \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Avirmax \/ Inapplicable"},{"orgOrder":0,"company":"Skyline Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SKG0106","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Skyline Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Skyline Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Skyline Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"National Eye Institute","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Funding","leadProduct":"Sonpiretigene Isteparvovec","moa":"MCO","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ National Eye Institute","highestDevelopmentStatusID":"5","companyTruncated":"Nanoscope Therapeutics \/ National Eye Institute"},{"orgOrder":0,"company":"Perfuse Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PER-001","moa":"Endothelin pathway","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Perfuse Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Perfuse Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Perfuse Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AmbioPharm","sponsor":"ONL Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ONL1204","moa":"Fas","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"AmbioPharm","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"AmbioPharm \/ ONL Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"AmbioPharm \/ ONL Therapeutics"},{"orgOrder":0,"company":"Endogena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EA-2351","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Endogena Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Endogena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Endogena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TRS02","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Tarsier Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Tarsier Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tarsier Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Kato Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Liposome-loaded Urea","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Kato Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kato Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kato Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Perceive Biotherapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Perceive Biotherapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0.080000000000000002,"dosageForm":"Intravitreal Injection","sponsorNew":"Perceive Biotherapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"5","companyTruncated":"Perceive Biotherapeutics \/ Johnson & Johnson"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SAR446597","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Selagine","sponsor":"Grifols International","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"GRF312","moa":"Cytokine","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Selagine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Selagine \/ Grifols International","highestDevelopmentStatusID":"5","companyTruncated":"Selagine \/ Grifols International"},{"orgOrder":0,"company":"HuidaGene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"HG004","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"HuidaGene Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Injection","sponsorNew":"HuidaGene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"HuidaGene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Plex Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"CAP4196","moa":"Alpha A crystallin","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Plex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Plex Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"Plex Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Kuria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KTX-1161","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Kuria Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Kuria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kuria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Enavogliflozin","moa":"SLC5A2","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Daewoong Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Daewoong Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SBI-100 OE","moa":"CB1 receptor","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sunitinib Analog","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Ashvattha Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ashvattha Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ashvattha Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Valitor","sponsor":"Morningside Ventures","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Series B Financing","leadProduct":"VLTR-557","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Valitor","amount2":0.029999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Valitor \/ Morningside Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Valitor \/ Morningside Ventures"},{"orgOrder":0,"company":"Cellusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CLS001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Cellusion","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cellusion \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cellusion \/ Inapplicable"},{"orgOrder":0,"company":"PulseSight Therapeutics","sponsor":"Pureos Bioventures","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2025","type":"Series A Financing","leadProduct":"PST-611","moa":"Transferrin","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"PulseSight Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PulseSight Therapeutics \/ Pureos Bioventures","highestDevelopmentStatusID":"5","companyTruncated":"PulseSight Therapeutics \/ Pureos Bioventures"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"MCO-020","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PulseSight Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"PST-611","moa":"Transferrin","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"PulseSight Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PulseSight Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"PulseSight Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eyestem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Retinal Pigment Epithelium Cell","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Eyestem","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eyestem \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Eyestem \/ Inapplicable"},{"orgOrder":0,"company":"Eluminex Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"EB-105","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Eluminex Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eluminex Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Eluminex Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"RevOpsis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Funding","leadProduct":"RO-104","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"RevOpsis Therapeutics","amount2":0.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"RevOpsis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"RevOpsis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kemwell Biopharma Private Limited","sponsor":"RevOpsis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Other Large Molecule","year":"2024","type":"Partnership","leadProduct":"RO-104","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Kemwell Biopharma Private Limited","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kemwell Biopharma Private Limited \/ RevOpsis Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Kemwell Biopharma Private Limited \/ RevOpsis Therapeutics"},{"orgOrder":0,"company":"Abpro","sponsor":"Atlantic Coastal Acquisition Corp II","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Merger","leadProduct":"ABP-201","moa":"ANG-2\/VEGF","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Abpro","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abpro \/ Atlantic Coastal Acquisition Corp II","highestDevelopmentStatusID":"5","companyTruncated":"Abpro \/ Atlantic Coastal Acquisition Corp II"},{"orgOrder":0,"company":"Abpro","sponsor":"YA II PN","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Private Placement","leadProduct":"ABP-201","moa":"ANG-2\/VEGF","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Abpro","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abpro \/ YA II PN","highestDevelopmentStatusID":"5","companyTruncated":"Abpro \/ YA II PN"},{"orgOrder":0,"company":"Scohia Pharma","sponsor":"Kuria Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"KTX-101","moa":"Nrf2","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Scohia Pharma","amount2":0.070000000000000007,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"Scohia Pharma \/ Kuria Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Scohia Pharma \/ Kuria Therapeutics"},{"orgOrder":0,"company":"Stuart Therapeutics","sponsor":"Glaukos","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"ST-113","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Stuart Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stuart Therapeutics \/ Glaukos","highestDevelopmentStatusID":"5","companyTruncated":"Stuart Therapeutics \/ Glaukos"},{"orgOrder":0,"company":"Character Biosciences","sponsor":"aMoon","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Series B Financing","leadProduct":"CTX203","moa":"ABCA1","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Character Biosciences","amount2":0.089999999999999997,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Character Biosciences \/ aMoon","highestDevelopmentStatusID":"5","companyTruncated":"Character Biosciences \/ aMoon"},{"orgOrder":0,"company":"Find Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"FTX-101","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Find Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Find Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Find Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Kala Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"KPI-012","moa":"Protease","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Kala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Kala Pharmaceuticals \/ Kala Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Kala Pharmaceuticals \/ Kala Pharmaceuticals"},{"orgOrder":0,"company":"Agtc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Agtc \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Agtc \/ Inapplicable"},{"orgOrder":0,"company":"Cellusion","sponsor":"Hangzhou Celregen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"CLS001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Cellusion","amount2":0.10000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Cellusion \/ Hangzhou Celregen Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Cellusion \/ Hangzhou Celregen Therapeutics"},{"orgOrder":0,"company":"RevOpsis Therapeutics","sponsor":"National Eye Institute","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Funding","leadProduct":"RO-104","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"RevOpsis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RevOpsis Therapeutics \/ National Eye Institute","highestDevelopmentStatusID":"5","companyTruncated":"RevOpsis Therapeutics \/ National Eye Institute"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"SAR446597","moa":"C1s","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Roca Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"RCT002","moa":"CXCR2\/DRAK1","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Roca Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Roca Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Roca Therapeutics \/ Undisclosed"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
